Can Clinical and Surgical Parameters Be Combined to Predict How Long It Will Take a Tibia Fracture to Heal? A Prospective Multicentre Observational Study: The FRACTING Study

Background. Healing of tibia fractures occurs over a wide time range of months, with a number of risk factors contributing to prolonged healing. In this prospective, multicentre, observational study, we investigated the capability of FRACTING (tibia FRACTure prediction healING days) score, calculated soon after tibia fracture treatment, to predict healing time. Methods. The study included 363 patients. Information on patient health, fracture morphology, and surgical treatment adopted were combined to calculate the FRACTING score. Fractures were considered healed when the patient was able to fully weight-bear without pain. Results. 319 fractures (88%) healed within 12 months from treatment. Forty-four fractures healed after 12 months or underwent a second surgery. FRACTING score positively correlated with days to healing: r = 0.63 (p < 0.0001). Average score value was 7.3 \ub1 2.5; ROC analysis showed strong reliability of the score in separating patients healing before versus after 6 months: AUC = 0.823. Conclusions. This study shows that the FRACTING score can be employed both to predict months needed for fracture healing and to identify immediately after treatment patients at risk of prolonged healing. In patients with high score values, new pharmacological and nonpharmacological treatments to enhance osteogenesis could be tested selectively, which may finally result in reduced disability time and health cost savings

Whole-Body Cryostimulation in Post-COVID Rehabilitation for Patients with Obesity: A Multidisciplinary Feasibility Study

Background: A post-COVID condition can reduce activity and quality of life, resulting in a significant socioeconomic and health burden. Understanding its impact on patients’ health is important for the development of personalized rehabilitation interventions. An independent association between obesity and post-COVID condition was found because of complications and comorbidities. Methods: Sixteen patients with obesity and post-COVID symptoms (i.e., dyspnea, pain, poor sleep quality, muscle fatigue), admitted to the Istituto Auxologico Italiano, Piancavallo (VB), Italy, were recruited for a four-week rehabilitation program including conventional exercise therapy, nutritional intervention, psychological support and whole-body cryostimulation (WBC). Results: All participants attended all sessions of the program. Anthropometric data showed statistically significant changes in weight, waist circumference and body mass index. Biochemical analyses showed significant reductions in lipid and inflammatory profiles. There was a significant improvement in physical performance, reduction in pain and improvement in psychological well-being. Conclusion: A multidisciplinary rehabilitation protocol including WBC, designed for patients with obesity and a post-COVID condition, is safe and feasible. The overall improvements demonstrate that multidisciplinary rehabilitation was effective on post COVID patients and suggest that the use of WBC is safe and could play a role as a booster in rehabilitation programs

A Potent (R)-alpha-bis-lipoyl Derivative Containing 8-Hydroxyquinoline Scaffold: Synthesis and Biological Evaluation of Its Neuroprotective Capabilities in SH-SY5Y Human Neuroblastoma Cells

A novel bis-lipoyl derivative containing 8-hydroxyquinoline scaffold (LA-HQ-LA, 5) was synthesized as a new multifunctional drug candidate with antioxidant, chelant, and neuroprotective properties for the treatment of neurodegenerative diseases. We have investigated the potential effectiveness of LA-HQ-LA against the cytotoxicity induced by 6-OHDA and H2O2 on human neuroblastoma SH-SY5Y cell line. Our outcomes showed that LA-HQ-LA resulted in significant neuroprotective and antioxidant effects against H2O2- and 6-OHDA-induced neurotoxicity in human neuroblastoma SH-SY5Y cells, as assessed by MTT assay. In particular, it showed potent neuroprotective effects against 6-OHDA in RA/PMA differentiated cells at all the tested concentrations

Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review

Congenital factor VII deficiency is a rare autosomal recessive disorder associated to different haemorrhagic manifestations. Labour and delivery may cause bleeding risk in patients with this coagulation deficit, thus it is appropriate to clarify whether prophylaxis of peripartum haemorrhage is necessary. To date, there are very few cases in scientific literature which report the management of women with congenital factor VII deficiency during labour, and a consensus for prophylaxis does not exist. In this manuscript we present the management of a 35 years old woman with factor VII deficiency, treated with recombinant factor VIIa before delivery, without haemorrhagic complications either for the woman and for the infant. Therefore, we present a review of similar cases managed with a peripartum prophylaxis with recombinant factor VIIa, and discuss its usefulness and effectiveness, in view of the severity of the deficit and the doses used

Pain Management During Office Hysteroscopy: A Survey of Hysteroscopists

Outpatient hysteroscopy can be a painful procedure for some patients and there is still no consensus regarding analgesia use. We evaluated which types and modalities of analgesia are most commonly used in a select group of hysteroscopists

Risk management in obstetrics: how to reduce the risk?

In this paper the authors examined the most important factors that in the pre-conception period can interfere in the evolution of pregnancy. They also reported a method that since the first trimester of pregnancy is able to identify women at higher risk of developing preeclampsia.   Proceedings of the 11th International Workshop on Neonatology and Satellite Meetings · Cagliari (Italy) · October 26th-31st, 2015 · From the womb to the adult Guest Editors: Vassilios Fanos (Cagliari, Italy), Michele Mussap (Genoa, Italy), Antonio Del Vecchio (Bari, Italy), Bo Sun (Shanghai, China), Dorret I. Boomsma (Amsterdam, the Netherlands), Gavino Faa (Cagliari, Italy), Antonio Giordano (Philadelphia, USA

The 12-month treatment with the oral contraceptive formulation containing dienogest (DNG) and estradiol valerate (E2V) shows beneficial effects on psychological symptoms: results from a prospective comparative study with a formulation containing ethinyl estradiol (EE) and drospirenone (DRSP)

The COCs evolution has been obtained with new and differents progestinic compounds associated with lower doses of EE (ethinylestradiol). The revolution in the COCs field is the introduction of estradiol valerate (E2V), ester of the natural estrogen, estradiol (E2) instead of EE. Dienogest (DNG) is the progestinic compound of the COC Klaira® associated with E2V in a multiphase formulation. DNG has a strong antiandrogenetic action without the mineralcorticoid and glucocorticoid action and E2V acts in this association improving the subjective sleep quality, somatic complaints, anxiety, vigilance, cognition and numerical memory. The EE/DRSP (drospirenone) association (Yaz®) has a progestinic compound characterized by antimineralcorticoid and antiandrogenic properties with a positive effect on psychological symptoms. In this prospective study we evaluated if E2V is able to exert the same psychological symptoms as EE/DRSP formulation. Psychological changes were evaluated with SCL90 for 5 cycles. In comparison with the basal value the score was significantly reduced (p<0,001) during both treatments. This effects observed confirm that DNG and DRSP act with beneficial effects on CN

The 12-month treatment with the oral contraceptive formulation containing dienogest (DNG) and estradiol valerate (E2V) shows beneficial effects on psychological symptoms: results from a prospective comparative study with a formulation containing ethinyl estradiol (EE) and drospirenone (DRSP)

The COCs evolution has been obtained with new and differents progestinic compounds associated with lower doses of EE (ethinylestradiol). The revo- lution in the COCs field is the introduction of estra- diol valerate (E2V), ester of the natural estrogen, estradiol (E2) instead of EE. Dienogest (DNG) is the progestinic compound of the COC Klaira associated with E2V in a multiphase formulation. DNG has a strong antiandrogenetic action without the mineral- corticoid and glucocorticoid action and E2V acts in this association improving the subjective sleep quality, somatic complaints, anxiety, vigilance, cog- nition and numerical memory. The EE/DRSP(drospirenone) association (Yaz®) has a progestinic compound characterized by antimineralcorticoid and antiandrogenic properties with a positive effect on psychological symptoms. In this prospective study we evaluated if E2V is able to exert the same psychological symptoms as EE/DRSP formulation. Psychological changes were evaluated with SCL90 for 5 cycles. In comparison with the basal value the score was significantly reduced (p&lt;0,001) during both treatments. This effects observed confirm that DNG and DRSP act with beneficial effects on CNS